



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vrignia 22313-1450 www.uspto.gov

APPLICATION NO. FILING DATE		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
09/019,441	(	02/05/1998	MITCHELL E. REFF	012712-502	2038	
909	7590	09/24/2003	•			
	PILLSBURY WINTHROP, LLP			EXAMINER		
P.O. BOX 10500 MCLEAN, VA 22102				HUYNH, PHUONG N		
WCLLAN,	V/1 22102	•			· · · · · · · · · · · · · · · · · · ·	
	•			ART UNIT	PAPER NUMBER	
		·		1644 DATE MAILED: 09/24/2003	42	

Please find below and/or attached an Office communication concerning this application or proceeding.

## **Advisory Action**

Application No.			Applicant(s)	
	09/019,441		REFF ET AL.	
	Examiner		Art Unit	
	Phuong Huynh		1644	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

THE REPLY FILED 21 August 2003 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.

Examination (RCE) in compliance with 37 GFR 1.114.
PERIOD FOR REPLY [check either a) or b)]
<ul> <li>a)</li></ul>
To6.07(f).  Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).
1. A Notice of Appeal was filed on Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.
2. The proposed amendment(s) will not be entered because:
<ul><li>(a)</li></ul>
(b) ⊠ they raise the issue of new matter (see Note below);
(c) ☐ they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or
(d) they present additional claims without canceling a corresponding number of finally rejected claims.
NOTE: See Continuation Sheet.
3. Applicant's reply has overcome the following rejection(s):
4. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).
5. The a) affidavit, b) exhibit, or c) request for reconsideration has been considered but does NOT place the application in condition for allowance because:
6. The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.
7. ☐ For purposes of Appeal, the proposed amendment(s) a) ☒ will not be entered or b) ☐ will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.
The status of the claim(s) is (or will be) as follows:
Claim(s) allowed: None.
Claim(s) objected to: None.
Claim(s) rejected: <u>42-70</u> .
Claim(s) withdrawn from consideration: None.
8. The proposed drawing correction filed on is a) approved or b) disapproved by the Examiner.
9. Note the attached Information Disclosure Statement(s)( PTO-1449) Paper No(s)
10. Other:

## Continuation Sheet (PTOL-303)



Continuation of 2. NOTE: The proposed amendment to claims 42 "nucleotides 58-390 of SEQ ID NO: 1...nucleotides 58-423 of SEQ ID NO: 2" and claim 48 "nucleotides 67-387 of SEQ ID NO: 3 ...nucleotides 58-411 of SEQ ID NO: 4" raises the issue of new matter and new issue that would require further consideration. Said phrases have no clear support in the specification and the claims as originally filed and Applicants have not pointed out the support for said phrases.

CHRISTINA CHAN
SUPERVISORY PATENT EXAMINER

TECHNOLOGY CENTER 1600